Your address will show here +12 34 56 78
CPE Capital
Dippers is a modified Nippers and surf education program that is open to all ages and abilities. The program was developed by Autism Swim (AS) and is run in collaboration with local Surf Life Saving Clubs (SLSC). The SLSC’s have a proven track record in water education and provide some of the volunteers needed to run a safe program.


The Dippers program is now in its 5th year and has expanded from its original location, Bondi, to five sites across New South Wales and one in Queensland:

  • Bronte
  • Coogee
  • Bondi
  • Port Macquarie


CPE Capital is pleased to support Autism Swim for the 3rd year running. Together with other partners, this support enables AS to run the program during summer.

About Autism Swim


Autism Swim is an  international charity, focused on wandering and drowning prevention for those who have Autism Spectrum Disorder (ASD) and other abilities. AS is the only certifying body in the world specific to ASD and aquatics. It also runs the award-nominated, modified nippers and surf education program, Dippers.

Find out about other programs CPE Capital supports


CPE Capital, Portfolio Company Announcement

CPE Capital (CPEC) has sold Cell Care to Generate Life Sciences, the world’s largest provider of newborn stem cell services and reproductive tissue banks.


During CPEC’s 2.5 year investment, Cell Care experienced consistent growth in EBITDA, including through the COVID-19 pandemic. The growth in CPEC’s equity value came from the successful implementation of several initiatives, including:


  • Entering into new hospital partnership agreements, particularly in Australia; 
  • Introducing new online marketing channels and increasing presence on social media;
  • Updating and optimising the pricing structure in Canada; and
  • Developing a number of other future growth initiatives including: the public bank partnership, entry into the NZ market and a new placental storage business.


This exit continues the CPEC 8 Fund’s strong momentum, following April’s sale of Gourmet Food Holdings.


CPE Capital, Portfolio Company Announcement

CPE Capital (CPEC) has sold its 100% interest in Gourmet Food Group (GFG) to Mondelez International. The global packaged food business, which is listed on the NASDAQ with a market capitalisation of US$75 billion, purchased GFG for A$454 million. 

In less than three years under our ownership, GFG grew EBITDA organically from A$17m to A$41m. This growth has come from the successful implementation of several initiatives, including:

  • new product development and category expansion;
  • doubling manufacturing capacity;
  • doubling of employees, with several key operational and finance hires, including COO and CFO;
  • significantly improved OH&S compliance procedures and financial reporting; and
  • material reductions in energy emissions.

CPEC looks forward to watching the continued success of the Gourmet Food brands under the ownership of Mondelez International.


CPE Capital

Winner of the 2019 CPE Capital Young Pioneer Award (The Award), Dr Nathan Zammit, has been internationally recognised for his work in medical immunology.


The Award provides important seed funding for innovative research ideas from outstanding early-mid career researchers.


Dr Zammit used this funding to understand how complex environmental cues shape the immune response and disease outcomes, with his findings supporting the importance of considering environmental impacts when investigating human disease and immune reactions.


The mouse model established in Dr Zammit’s work has already been applied to research which aims to understand the effect of individual drugs or gene variants on human health.


According to Dr Zammit, the model will be a vital resource for The Garvan Institute of Medical Research


“As we have witnessed this year by the COVID-19 pandemic, patient outcomes can differ widely based on personal history that is molded by environment, genetics, and age, underlining the importance of our research,” Dr Zammit said.


Dr Zammit’s work has received international recognition, and has resulted in his recruitment to Harvard Medical School, where he’ll take a postdoctoral research position in January 2021.


CPE Capital has been supporting the Young Pioneer Award since 2014.


CPE Capital

Children with autism are 160 times more likely to drown than their peers but local program, Dippers, is helping to change that.


Dippers is a surf education program (a modified Nippers) that has been developed and run by Autism Swim, an organisation founded on the belief that everyone has the right to survive and thrive in the water. The program is run in collaboration with local Surf Life Saving Clubs and is open to all ages and abilities.


CPE Capital is pleased to have been able to support Autism Swim to run its program this summer.

The Dippers program is in its fourth year. The program provides vital water skills to those who may otherwise not have the opportunity. Each participant is supported in a 2:1 or 3:1 capacity and has the opportunity to work toward their individual goals. These may include putting their face in the water, riding a board, learning when to go over or under a wave or  the ability to interact socially with others.

About Autism Swim

Autism Swim is an  international charity, focused on wandering and drowning prevention for those who have Autism Spectrum Disorder (ASD) and other abilities.

Find out about other programs CPE Capital supports


CPE Capital

From today, Australasia’s pioneering and most experienced institutional private capital manager has refreshed and extended its brand to become CPE Capital, capturing the firm’s entire 32 year history under one name.


“As we work towards our 40th anniversary, CPE Capital is a name that embraces the firm’s full history.” CEO John Haddock said.


The firm was founded in 1987 by industry pioneers Bill Ferris AC and Joe Skrzynski AO as Australian Mezzanine Investments.  In 2000, a joint venture was entered into with Castle Harlan Inc from New York to form Castle Harlan Australian Mezzanine Partners, later referred to as CHAMP Private Equity.  Over the last five years the firm’s leadership has successfully transitioned to the next generation, a first of its kind in Australasia.  At this time it is also acknowledged that the prior arrangements with Castle Harlan and CHAMP Ventures have concluded.


This brand refresh highlights the firm’s unique 32 year history:


  • Net returns to investors on all exited deals have delivered a compound annual return of 21% pa, compared to the ASX All Ordinaries Accumulation Index return of 9.5% pa over the same period.


  • Ten landmark investments over this time have averaged a 6x return by turning ~$410m of investors’ equity into ~$2,520m of cash proceeds.


  • 289 millionaires have been created from former portfolio company executives who have invested alongside the firm.


“CPE Capital’s experience and performance over 32 years across all market cycles and aspects of the private capital business in Australasia is unique and a foundation for the delivery of future superior investment returns.”  CEO John Haddock said.


About CPE Capital


CPE Capital (“CPEC”) is Australasia’s most experienced private capital manager having been managing institutional private capital investments since 1987.  Over the last 32 years the firm has made 75 platform investments across eight funds through the deployment of A$3.8 billion in investor commitments.  Founded by industry pioneers Bill Ferris AC and Joe Skrzynski AO, since 2014 the firm has been managed by its next generation, making it Australasia’s first successful private equity leadership transition.


CPEC undertakes control buyout transactions, enters into founder partnerships and provides growth investments for mid-market companies in Australasia, including those which possess significant offshore operations or ambitions. 


CPEC’s long history of sustainable performance across all investment cycles is based on its ability to identify situations and opportunities that offer growth on a risk adjusted basis. 


Experience, flexibility, nimbleness and a specialist functional team structure are CPEC’s core attributes.



For media enquiries please contact:

Rob Dempsey

+61 419 888 831

+61 2 8248 8860



CPE Capital
On Thursday evening, the Garvan Institute of Medical research held its annual Researcher Awards. The awards provide important seed funding for innovative research ideas from outstanding early-mid career researchers.

At the event, Professor Marie Dziadek, Chief Scientific Officer at the Garvan Institute of Medical Research said: “Research prizes and awards funded by generous organisations provide great support for innovative science. They allow our researchers to push the boundaries and test ideas to support their applications for significant peer reviewed funding.

“We’re extremely grateful to CHAMP Private Equity, the Joseph Palmer Foundation and Ridley Corporation, who we’ve had long relationships with.” 

CHAMP’s Young Pioneer Award provides $10,000 in funding for initial experiments for an early-mid career researcher to test a new idea. Dr Nathan Zammit, from the Transplant Immunology Laboratory, received the 2019 award for ‘the TGN1412 trial, an immunological mystery’. The TGN1412 clinical trial tested a novel immunomodulatory drug, that began with great promise to treat autoimmunity and prevent rejection of transplanted organs. However, the trial abruptly ended after multi-organ failure was rapidly developed in the 6 healthy participants.

Dr Zammit has put forward a hypothesis for why this happened and why it was not predicted in pre-clinical testing. He will be able to test this hypothesis with the funding from this award.

CHAMP is pleased to continue its long-standing relationship with the Garvan Institute of Medical Research. 

Find out more about the 2019 Garvan Researcher Awards.

CPE Capital
Leading global supplier of precision engineered solutions, Marand Precision Engineering Pty Ltd (Marand), today announced that it had reached an agreement to sell the company to funds managed by CHAMP Private Equity (CHAMP). The terms of the transaction are confidential.

Marand supplies sophisticated engineering solutions to the defence, aerospace, rail, automotive and mining sectors. Its customer base is predominately multinational blue chip organisations including Lockheed Martin, Boeing, BAE Systems, BHP and Rio Tinto, for which it designs and manufactures complex innovative solutions.

“My father Andy Ellul founded Marand in 1969 and last week we were delighted to celebrate the company’s 50th anniversary,” said David Ellul, Executive Chairman of Marand.

“Over five decades, Marand has evolved from a machine tools and equipment supplier to the automotive industry to being recognised as Australia’s leading precision engineering company and Australia’s largest supplier into the F-35 Joint Strike Fighter program. We consider CHAMP a fantastic custodian of the business, who will help ensure Marand maintains its innovative culture and reaches its full potential.”

“While the terms of the transaction remain confidential, the Ellul family retains an investment in the business,” he said.

Rohan Stocker, CEO of Marand said, “This is a wonderful opportunity to facilitate further growth in the business. Marand’s innovative engineering, advanced manufacturing and sustainment capabilities will continue to add value to our customers and we are excited by the prospect of working with CHAMP to take the business to the next stage in its development”.

The CHAMP Group is one of Australia’s most experienced private equity managers, having first raised institutional capital more than 30 years ago. Since that time, CHAMP has made more than 90 investments and deployed more than A$3.7 billion in equity capital. CHAMP has one of the largest dedicated investment teams in the country. The investment will sit within the CHAMP IV Fund, alongside companies including Cell Care, Gourmet Food, StraitNZ and Dutton Garage.

The agreement is subject to regulatory and other customary approvals.

KPMG Corporate Finance acted as corporate advisers to Marand and the Ellul family, alongside Gadens Legal and Dobbyn and Carafa.

For further information on Marand, visit

Media Contact – Marand
Alex Lyon Marand
Business Development Manager
+61 417 384 223

Media Contact – CHAMP
Rob Dempsey
+61 419 888 831

CPE Capital

CHAMP Private Equity took two divisions of Constellation Brands and turned them into a diversified portfolio of premium wine brands. It has secured a more than 5x money multiple for its efforts

In wine, companies get one chance a year for about six weeks when the grapes are harvested to make improvements to the production process. In the event of a bad vintage, brands with a reputation to maintain could have to wait two years before they can muster the quantity or quality they need.

The combination of lifestyle marketing potential and long-cycle agribusiness risk that characterizes this fragmented segment suggests an interesting private equity opportunity – but only for those who are sufficiently diligent about its cultural and operational nuances. This was the philosophy that underpinned CHAMP Private Equity’s investment in Australia-based Accolade Wines, which will be sold to The Carlyle Group for A$1 billion ($770 million). The GP is set for a more than 5x return on the deal.

Its strategy focused on leveraging the Australian wine industry’s unique overlaps between brand platform building capacity, primary production strengths, and competitive access to increasingly sophisticated Asian markets. John Haddock, CEO of CHAMP, describes the result as not only the centerpiece of its third fund, but the creation of a local champion. 

“I’m not sure that something of this scale or value-add has been done in Australian private equity,” he says. “This is a global company that’s based out of Australia making two-thirds of its earnings offshore, physically exporting nearly $400 million a year of product to 140 countries, and it’s in the top five consumer goods companies in its category. It talks to what private equity can do.”

CHAMP paid A$290 million for an 80% stake in the Australian and UK wine divisions of US-based Constellation Brands in 2010, fusing them into a single, capital-light acquisition platform under the Accolade banner. In addition to rejuvenating longstanding brands such as Hardys and Grant Burge, the portfolio was slanted toward more premium offerings and expanded to cover five continents.

Dividends delivered by organic growth, however, were a major factor in generating CHAMP’s ultimate return. Accolade experienced rapid earnings growth as hierarchical decisioning processes were streamlined and new management was introduced. In 2010, the company was revenue generating at only a break-even rate, but this was enough to allow the negotiation of asset-based debt packages with GE Capital that were the primary bolt-on financing mechanisms.

All the while, the winemaking families of Hardy and Burge have remained passionately involved in the stewardship of their namesake products. CHAMP sees these human-level commitments as the key to success in the wine game. Notably, part the Accolade turnaround included paying off a GBP40 million ($57 million) employee pension deficit in Constellation’s UK division.

“It’s a very personal product so you need to be careful in the way in which you go about the management of the business,” says Haddock. “The advice I provided Carlyle is that they’ll be most successful if they understand to some degree they’re a custodian of heritage assets for families and the wine industry in general.”


CPE Capital, Portfolio Company Announcement
2018 AVCAL Annual Awards Recognise the Industry’s Best.

CHAMP Private Equity wins the award for the “Best Upper Mid-Cap Investment between $250 million and $500 million” for their investment in Accolade Wines.

At the industry’s 25th anniversary marquee annual event, the Australian Private Equity and Venture Capital Association Limited (AVCAL) handed out awards to a number of outstanding firms and industry leaders.

“The private capital investment industry in Australia plays a significant role in growing businesses, creating new jobs, and nurturing a more innovative and dynamic Australian economy, these awards recognise the contributions that make that happen, said AVCAL Chief Executive, Mr Yasser El-Ansary.

More than 450 of the private capital industry’s leaders are gathered at the annual AVCAL Conference this year, with the awards event concluding two days of thought-provoking discussion and debate about the big issues which will shape the future of Australia, and global financial services markets over the next decade.

“When you bring the power of our collective industry together, you see very clearly the potential for private capital investors to drive big shifts in the economy in areas such as energy, healthcare and data,” added Mr El-Ansary.

Award winners in a number of categories were celebrated at tonight’s event, including a number of special awards for industry pioneers who have played a role in growing private capital in Australia over the past 25 years.

“All of the award winners are leaders who have demonstrated exceptional investment execution strategy through the work they have done to grow and expand good businesses, transforming them into great businesses,” said Mr El-Ansary.